search
Back to results

Short-term Effect of Extended-release Niacin on Endothelial Function.

Primary Purpose

Hypoalphalipoproteinemia

Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
Niacin
Sponsored by
University of Campinas, Brazil
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Hypoalphalipoproteinemia focused on measuring Niacin, Endothelial function, Laropiprant, HDL

Eligibility Criteria

20 Years - 60 Years (Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • asymptomatic individuals
  • plasma HDL-C levels <40 mg/dL

Exclusion Criteria:

  • symptomatic atherosclerotic disease
  • diabetes
  • liver disease
  • renal disease
  • thyroid dysfunction
  • indication for or use of lipid-lowering treatment in the last six months
  • use of anti-inflammatory treatment in the last 30 days
  • current or previous diagnosis of cancer or immune inflammatory diseases
  • chronic obstructive pulmonary disease
  • infectious disease manifested in the last 3 months
  • body mass index ≥ 26 kg/m2

Sites / Locations

  • University of Campinas

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Niacin/Laropiprant

Niacin

Arm Description

Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)

Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)

Outcomes

Primary Outcome Measures

The short-term effect of niacin on endothelial function.
Endothelial-dependent vasodilation was assessed by ischemia-induced reactive hyperemia of the brachial artery by using an ultrasound equipment

Secondary Outcome Measures

Plasma C-reactive protein levels
Systemic inflammatory activity as estimated by the plasma concentration of C-reactive protein
HDL-C and HDL size
Plasma concentration of high-density lipoprotein (HDL) cholesterol and HDL size

Full Information

First Posted
September 10, 2013
Last Updated
September 10, 2013
Sponsor
University of Campinas, Brazil
search

1. Study Identification

Unique Protocol Identification Number
NCT01942291
Brief Title
Short-term Effect of Extended-release Niacin on Endothelial Function.
Official Title
Short-term Effect of Extended-release Niacin With and Without the Addition of Laropiprant on Endothelial Function
Study Type
Interventional

2. Study Status

Record Verification Date
September 2013
Overall Recruitment Status
Completed
Study Start Date
March 2012 (undefined)
Primary Completion Date
December 2012 (Actual)
Study Completion Date
June 2013 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Campinas, Brazil

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Individuals with reduced plasma concentration of high-density lipoprotein (HDL) cholesterol are more susceptible to oxidative stress and often present reduced endothelial function, which has been mainly related to this susceptibility. Studies in animal and cell models have demonstrated that niacin activates both GPR-109A in leukocytes and heme oxygenase-1 (HO-1) pathway promoting strong anti-inflammatory and anti-oxidative effects. . In this context, the aim of this study was to investigate the short-term effect of niacin on endothelial function and verify the existence of interaction of PGD2 receptor antagonist, i.e. laropiprant (LRPT), in subjects with low HDL-cholesterol (HDL -C).
Detailed Description
Study design and treatments The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil). Medications were kindly supplied by Libbs and Merck. Plasma samples and brachial artery reactivity were obtained at baseline, 7th day of treatment 1, 7th day after washout and 7th day of treatment 2. Study Measurements The following blood measurements were performed using the Modular Hitachi system and Roche Diagnostics (Mannheim, Germany) reagents: glucose (GOD-PAP), triglycerides (TG)(GPO-PAP), HDL-C (HDL-C plus 3rd generation) and C-reactive protein (CRP) (high-sensitivity CRP, Cardiophase, Dade Behring, Marburg, Germany). LDL cholesterol was calculated by the Friedewald formula. HDL size was measured by laser scattering (Zetasizer - Nanoseries DTS 1060, Malvern Instruments, Worcestershire, UK). Total and direct bilirrubin was measured by the Jendrassik-Grof method (Roche/Hitachi analyzer). The cholesteryl ester transfer protein activity was measured by an endogenous assay. Aliquots of the whole plasma (in which LCAT activity was inhibited by DTNB 9 μL/mL) were added to HDL-[3H]cholesteryl ester fractions and simultaneously incubated at 4°C and 37°C for 4h. Apo-B containing lipoproteins, present in the incubation mixture, were then precipitated; the CE radioactivity in the supernatant represented the net rate at which CE mass was transferred and values expressed as percent of [3H] cholesteryl ester transferred/4 hours depended upon the plasma concentrations of HDL, TG-rich lipoproteins and CETP simultaneously. Endothelial-dependent vasodilation was assessed by ischemia-induced reactive hyperemia. Briefly, after 12-hour overnight fasting patients were examined at 8 a.m. in a quiet room at 22ºC by using a ultrasound equipment Vivid i (GE Healthcare, Wauwatosa, WI, USA) with a high-resolution (up to 13 MHz) vascular probe (12l-RS, GE Healthcare, Wauwatosa, WI, USA) in B-mode. The cardiac cycles were monitored simultaneously by electrocardiography coupled to the equipment. Flow-mediated dilation (FMD) was assessed after 5-minutes inflation of a cuff placed below the transducer, 50 mm Hg above the systolic blood pressure. Two-dimensional images of the brachial artery were obtained during 5 minutes from the longitudinal axis approximately 5-10 cm above the antecubital fossa. The maximum expansion of the diameter of the brachial artery was measured in triplicate at the peak of the T wave of the cardiac cycle before the interruption of the flow and post deflation.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypoalphalipoproteinemia
Keywords
Niacin, Endothelial function, Laropiprant, HDL

7. Study Design

Primary Purpose
Basic Science
Study Phase
Phase 4
Interventional Study Model
Crossover Assignment
Masking
ParticipantInvestigator
Allocation
Randomized
Enrollment
18 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Niacin/Laropiprant
Arm Type
Experimental
Arm Description
Extended-release niacin 1g/day associated with Laropiprant 1g/20mg (ERN/LRPT, Cordaptive, Merck, Sao Paulo, Brazil)
Arm Title
Niacin
Arm Type
Experimental
Arm Description
Extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmaceutica, Sao Paulo, Brazil)
Intervention Type
Drug
Intervention Name(s)
Niacin
Other Intervention Name(s)
Nicotinic acid, Vitamin B3
Intervention Description
The study was randomized, double-blind, controlled, using a 2-way crossover design with both treatment periods and washout time lasting 7 days. Subjects were allocated by simple randomization to extended-release niacin 1g/day alone (ERN, Metri, Libbs Farmacêutica, São Paulo, Brazil) or niacin associated with LRPT 1g/20mg (ERN/LRPT, Cordaptive, Merck, São Paulo, Brazil).
Primary Outcome Measure Information:
Title
The short-term effect of niacin on endothelial function.
Description
Endothelial-dependent vasodilation was assessed by ischemia-induced reactive hyperemia of the brachial artery by using an ultrasound equipment
Time Frame
7 days
Secondary Outcome Measure Information:
Title
Plasma C-reactive protein levels
Description
Systemic inflammatory activity as estimated by the plasma concentration of C-reactive protein
Time Frame
7 days
Title
HDL-C and HDL size
Description
Plasma concentration of high-density lipoprotein (HDL) cholesterol and HDL size
Time Frame
7 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
60 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: asymptomatic individuals plasma HDL-C levels <40 mg/dL Exclusion Criteria: symptomatic atherosclerotic disease diabetes liver disease renal disease thyroid dysfunction indication for or use of lipid-lowering treatment in the last six months use of anti-inflammatory treatment in the last 30 days current or previous diagnosis of cancer or immune inflammatory diseases chronic obstructive pulmonary disease infectious disease manifested in the last 3 months body mass index ≥ 26 kg/m2
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Andrei C Sposito, PhD
Organizational Affiliation
University of Campinas
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Campinas
City
Campinas
State/Province
SP
ZIP/Postal Code
13083-887
Country
Brazil

12. IPD Sharing Statement

Citations:
PubMed Identifier
24768191
Citation
Nasser Figueiredo V, Vendrame F, Colontoni BA, Quinaglia T, Roberto Matos-Souza J, Azevedo Moura F, Coelho OR, de Faria EC, Sposito AC. Short-term effects of extended-release niacin with and without the addition of laropiprant on endothelial function in individuals with low HDL-C: a randomized, controlled crossover trial. Clin Ther. 2014 Jun 1;36(6):961-6. doi: 10.1016/j.clinthera.2014.03.012. Epub 2014 Apr 24.
Results Reference
derived

Learn more about this trial

Short-term Effect of Extended-release Niacin on Endothelial Function.

We'll reach out to this number within 24 hrs